FDA panel supports Astaire's bladder hyperactivity drugs

Source: China Council for the promotion of drugs 2012-04-06 (Reuters) - Tokyo based Astaire Pharmaceutical Co announced Thursday that its mirabegron, a drug used to treat bladder hyperactivity, has won the support of an FDA advisory panel Overactive bladder, or OAB for short, is a urinary system disease that causes sudden and unstoppable urination, even if only a small amount of urine is in the bladder Mirabegron of Estella is a selective SS3 adrenergic receptor agonist, administered orally and once a day, to improve the storage capacity of the bladder and reduce bladder contraction during urination The FDA expert panel reviewing mirabegron's new drug application recommended approval for the treatment of bladder hyperactivity disorder with 7 votes in favor of 4 votes against 1 abstention FDA's final decision is June 29, 2012 Although not binding, FDA generally endorses the recommendations of its panel of experts Mirabegron's applications for registration in several other countries are also under review Mirabegron was approved in Japan in July 2011 and listed in September 2011 IMS Health, a pharmaceutical market research firm, estimates that more than 30 million people suffer from OAB in the United States, where the market value of prescription drugs is about $200 million a year FDA approved drugs for bladder hyperactivity disorder include: Ansteel owns the brand drug vesicare of solifenacin, Novartis' Daphne is on sale under the brand name of enablex, Pfizer's fesoterodine is on sale under the brand name of toviaz, tolterodine is on sale under the brand names of detrol and detrola, trospium is on sale under the brand names of sanctura and sanctura XR On sale, Wahson pharmaceutical company's oroxi Bunin is listed on the brand name Ditropan, Ditropan XL, Oxytrol and external gel known as Gelnique In December last year, FDA approved topical gel for treating OAB was Anturol of AIS pharmaceutical company More than 200 million people around the world are expected to have bladder hyperactivity disorder, according to the global industrial analysis company The global market for drugs for the treatment of overactive bladder is expected to exceed $4 billion by 2017 Original link: http://